Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
(31 sites) United States
The University of South Alabama, Mitchell Cancer Institute, Mobile, Alabama University of Arizona Cancer Center, Tucson, Arizona City of Hope, Duarte, California UC San Diego Health - Moores Cancer Center, La Jolla, California Hoag Gynecologic Oncology, Newport Beach, California UCI Health Chao Family Comprehensive Cancer Center, Orange, California AdventHealth Cancer Institute, Orlando, Florida Sarasota Memorial Research Institute, Sarasota, Florida Emory University, Atlanta, Georgia Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana Holy Cross Hospital, Silver Spring, Maryland University of Michigan, Ann Arbor, Michigan Karmanos Cancer Institute, Detroit, Michigan Washington University School of Medicine, St Louis, Missouri Mercy Hospital St. Louis, St Louis, Missouri Women's Cancer Center of Nevada, Las Vegas, Nevada Center of Hope, Reno, Nevada Stony Brook Cancer Center, Stony Brook, New York Levine Cancer Institute, Charlotte, North Carolina East Carolina University, Greenville, North Carolina Cleveland Clinic, Cleveland, Ohio OhioHealth Research Institute, Columbus, Ohio Kettering Health, Kettering, Ohio ProMedica Flower Hospital, Sylvania, Ohio Oklahoma University Health Stephenson Cancer Center, Oklahoma City, Oklahoma AHN West Penn Hospital, Pittsburgh, Pennsylvania Hollings Cancer Center, Charleston, South Carolina Erlanger Health, Inc., Chattanooga, Tennessee Baylor College of Medicine, Houston, Texas University of Texas Science Center at Houston, McGovern Medical School, Houston, Texas Providence Sacred Heart Medical Center & Children's Hospital, Spokane, Washington